Program
elranatamab
Also written as “Elranatamab”, “Elranatamab (PF-06863135)” and “Elranatamab + Nirogacestat”.
Its studies are mostly in Multiple Myeloma, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 137 open or running | phase 4since Sep 5, 2023 | Aug 16, 2017 | Aug 4, 2027phase 3 · NCT05317416 |
| Bristol-Myers Squibb | 11 open or running | phase 2since May 16, 2025 | May 16, 2025 | May 31, 2027phase 2 · NCT06988488 |
| Hoffmann-La Roche | 11 open or running | phase 1since Jun 22, 2023 | Jun 22, 2023 | Jul 31, 2027phase 1 · NCT05927571 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Aug 16, 2017.
- Nov 6, 2020Phase 2 study in Multiple MyelomaPfizer · NCT04649359 · 187 enrolled · United States, Australia, Belgium and more
- Mar 1, 2021Phase 1 study in RecurrencePfizer · NCT04798586 · 4 enrolled · Japan
- Aug 3, 2021Phase 2 study in Multiple MyelomaPfizer · NCT05014412 · 86 enrolled · United States, Japan, Taiwan and more
- Aug 11, 2021Phase 3 study in Multiple MyelomaPfizer · NCT05020236 · 893 planned · United States, Argentina, Australia and more
- Oct 8, 2021Phase 2 study in Multiple MyelomaPfizer · NCT05090566 · 46 enrolled · United States, Canada
- Jan 5, 2022Phase 2 study in Neoplasms, Plasma CellPfizer · NCT05228470 · 39 enrolled · China
- Mar 18, 2022Phase 3 study in Multiple MyelomaPfizer · NCT05317416 · 854 enrolled · United States, Australia, Austria and more
- Oct 26, 2022Phase 3 study in Multiple MyelomaPfizer · NCT05623020 · 1,060 planned · United States, Argentina, Australia and more
- Jun 22, 2023Hoffmann-La Roche's first study: phase 1 study in RecurrenceNew to Hoffmann-La RocheHoffmann-La Roche · NCT05927571 · 120 planned · Australia, Israel, South Korea
- Sep 5, 2023Phase 4 study in Multiple MyelomaPfizer · NCT06057402 · 80 planned · United States, Australia, Canada and more
- Nov 17, 2023Phase 3 study in Multiple MyelomaPfizer · NCT06152575 · 492 planned · United States, Argentina, Australia and more
- Jan 10, 2024Phase 1 study in Multiple MyelomaPfizer · NCT06215118 · 100 enrolled · United States, Australia, Canada
- May 16, 2025Bristol-Myers Squibb's first study: phase 2 study in Multiple MyelomaNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT06988488 · 62 planned · United States, Canada, China and more
- Oct 13, 2026Phase 4 study in Multiple MyelomaPfizer · NCT07881835 · 75 planned
Ahead
- May 31, 2027Primary completion: phase 2 study in Multiple MyelomaBristol-Myers Squibb · NCT06988488
- Jul 31, 2027Primary completion: phase 1 study in RecurrenceHoffmann-La Roche · NCT05927571
- Aug 4, 2027Primary completion: phase 3 study in Multiple MyelomaPfizer · NCT05317416
- Nov 16, 2027Primary completion: phase 1 study in Multiple MyelomaPfizer · NCT06215118
TargetBeta
“A bispecific monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, ”NCIt, by rule
“T cell surface glycoprotein CD3 binding agent; Tumor necrosis factor receptor superfamily member 17 binding agent”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| linvoseltamabrule | Regeneron Pharmaceuticals | phase 4 | 13 |
| teclistamabrule | Johnson & Johnson | phase 4 | 11 |
| etentamig | AbbVie | phase 3 | 11 |
| ramantamig | Johnson & Johnson | phase 3 | 7 |
| Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 | Sino Biopharmaceutical | phase 3 | 4 |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 4 |
| cizutamigrule | UCB | phase 2 | 5 |
| vonsetamigrule | Regeneron Pharmaceuticals | phase 2 | 3 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
| LVV Expressing VSV Glycoprotein/Anti-CD3 scFv Containing Transgene Encoding for Anti-BCMA CAR KLN-1010rule | kelonia-therapeutics-inc | phase 1 | 1 |
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07881835Multiple Myeloma | 4 | Not yet recruiting | Pfizer | Feb 16, 2029 | 75 |
| NCT06988488Multiple Myeloma · United States, Canada, China and more | 2 | Recruiting | Bristol-Myers Squibb | May 31, 2027 | 62 |
| NCT06215118Multiple Myeloma · United States, Australia, Canada | 1 | Active, not recruiting | Pfizer | Nov 16, 2027 | 100 |
| NCT06152575Multiple Myeloma · United States, Argentina, Australia and more | 3 | Recruiting | Pfizer | Aug 26, 2026 | 492 |
| NCT06057402Multiple Myeloma · United States, Australia, Canada and more | 4 | Recruiting | Pfizer | Feb 22, 2032 | 80 |
| NCT05927571Recurrence · Australia, Israel, South Korea | 1 | Recruiting | Hoffmann-La Roche | Jul 31, 2027 | 120 |
| NCT05623020Multiple Myeloma · United States, Argentina, Australia and more | 3 | Recruiting | Pfizer | Oct 18, 2030 | 1,060 |
| NCT05317416Multiple Myeloma · United States, Australia, Austria and more | 3 | Active, not recruiting | Pfizer | Aug 4, 2027 | 854 |
| NCT05228470Neoplasms, Plasma Cell · China | 2 | Completed | Pfizer | Aug 6, 2023 | 39 |
| NCT05090566Multiple Myeloma · United States, Canada | 2 | Terminated | Pfizer | Feb 13, 2025 | 46 |
| NCT05020236Multiple Myeloma · United States, Argentina, Australia and more | 3 | Recruiting | Pfizer | Feb 26, 2026 | 893 |
| NCT05014412Multiple Myeloma · United States, Japan, Taiwan and more | 2 | Completed | Pfizer | Jun 15, 2023 | 86 |
| NCT04798586Recurrence · Japan | 1 | Completed | Pfizer | May 27, 2022 | 4 |
| NCT04649359Multiple Myeloma · United States, Australia, Belgium and more | 2 | Completed | Pfizer | Jun 17, 2022 | 187 |
| NCT03269136Multiple Myeloma · United States, Canada | 1 | Completed | Pfizer | Jan 19, 2024 | 101 |
How it is read
Names in the registry
- “Elranatamab”, 12 entries
- “Elranatamab (PF-06863135)”, 2 entries
- “Elranatamab + Nirogacestat”, 1 entry
- “Elranatamab + lenalidomide + dexamethasone”, 1 entry
- “PF-06863135 monotherapy IV or SC”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 15 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.